Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line

Blood (2016) 128 (22): 3076.

https://doi.org/10.1182/blood.V128.22.3076.3076

Published: 2016

Journal Articles

Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML

Domenico Russo, MD, Giovanni Martinelli, Michele Malagola, Valeria Cancelli, Cristina Skert, MD, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Diamante Turri, Salvatore Mirto, MD, Marco Gobbi, MD, Ivana Pierri, MD, Umberto Vitolo, Patrizia Pregno, MD, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, MD, Francesco Di Raimondo, MD, Fabio Stagno, MD PhD, Giuliana Alimena, Massimo Breccia, MD, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, MD, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, MD, Giuseppina Nicolini, Paolo de Fabritiis, MD, Elisabetta Abruzzese, MD, Renato Fanin, MD, Mario Tiribelli, MD, Piero Galieni, MD, Catia Bigazzi, Giorgina Specchia, MD, Emanuele Angelucci, Emilio Usala, MD, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, MD PhD, Monia Lunghi, MD, Francesco Lauria, MD, Monica Bocchia, MD, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, MD, Valeria Santini, Giovanni Quarta, MD, Mariella Girasoli, Giuseppe Fioritoni, MD, Roberto Di Lorenzo, Bruno Mario Cesana, Gianantonio Rosti

Blood (2014) 124 (21): 1794.

https://doi.org/10.1182/blood.V124.21.1794.1794

Published: 2014

Journal Articles

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

Blood (2013) 121 (26): 5138–5144.

https://doi.org/10.1182/blood-2013-01-480194

Published: 2013

Includes: Supplemental data

Journal Articles

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

Domenico Russo, Michele Baccarani, MD, Giovanni Martinelli, MD, Chiara Colombi, Michele Malagola, Cristina Skert, MD, Simona Soverini, Ilaria Iacobucci, PhD, Diamante Turri, MD, Salvatore Mirto, Marco Gobbi, MD, Ivana Pierri, Umberto Vitolo, MD, Patrizia Pregno, MD, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, MD, Fabio Stagno, Giuliana Alimena, Massimo Breccia, Francesco Nobile, MD, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, M.D., Francesco Lauria, MD, Monica Bocchia, Francesco Rodeghiero, MD, Anna D'Emilio, Alberto Bosi, MD, Valeria Santini, MD, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, MD, Roberto Di Lorenzo, Bruno Cesana, Gianantonio Rosti, MD

Blood (2011) 118 (21): 1682.

https://doi.org/10.1182/blood.V118.21.1682.1682

Published: 2011

Journal Articles

Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509

Domenico Russo, Giuliana Alimena, Chiara Colombi, Massimo Breccia, Simona Soverini, Ilaria Iacobucci, PhD, Federica Cattina, MD, Giovanni Martinelli, MD, Nicoletta Testoni, Anna Marina Liberati, Viviana Appolloni, Mario Tiribelli, Renato Fanin, Felicetto Ferrara, MD, Mario Annunziata, MD, Elena Trabacchi, Daniele Vallisa, MD, Antonio De Vivo, Fausto Castagnetti, Miriam Fogli, Sandra Durante, Francesco Di Raimondo, MD, Fabio Stagno, A. M. Carella, G. Pica, Alessandra Iurlo, M.D., Tommaso Radice, Patrizia Pregno, MD, Umberto Vitolo, MD, Elisabetta Abruzzese, Paolo de Fabritiis, Maurizio Longinotti, MD, Simonetta Pardini, Caterina Musolino, MD, Sabina Russo, Marco Gobbi, MD, Ivana Pierri, Gianluca Gaidano, Monia Lunghi, M.D., Giuseppe Visani, Sara Barulli, Mario Cazzola, Serena Merante, Cristina Skert, MD, Michele Malagola, Gianantonio Rosti, MD, Michele Baccarani, MD

Blood (2011) 118 (21): 786.

https://doi.org/10.1182/blood.V118.21.786.786

Published: 2011

Journal Articles

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Domenico Russo, Giovanni Martinelli, Michele Malagola, MD, Chiara Colombi, Giantonio Rosti, Marilina Amabile, Miriam Fogli, Diamante Turri, Salvatore Mirto, Marco Gobbi, Ivana Pierri, Umberto Vitolo, Patrizia Pregno, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, Fabio Stagno, MD, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Vincenzo Liso, MD, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, Francesco Lauria, Monica Bocchia, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, Valeria Santini, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, Roberto Di Lorenzo, Nicoletta Testoni, Antonio De Vivo, Simona Soverini, Ilaria Iacobucci, Michele Baccarani, Michele Baccarani

Blood (2010) 116 (21): 3412.

https://doi.org/10.1182/blood.V116.21.3412.3412

Published: 2010

Journal Articles

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Domenico Russo, Gianantonio Rosti, Giovanni Martinelli, Michele Malagola, Salvatore Mirto, Diamante Turri, Marco Gobbi, Ivana Pierri, Umberto Vitolo, MD, Patrizia Pregno, Francesco Di Raimondo, M.D., Fabio Stagno, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, MD, Tamara Intermesoli, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Vincenzo Liso, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, Sabina Russo, Gianluca Gaidano, MD, Monia Lunghi, Francesco Lauria, MD, Monica Bocchia, Francesco Rodeghiero, MD, Anna D'Emilio, MD, Giovanni Quarta, Mariella Girasoli, Alberto Bosi, Valeria Santini, Giuseppe Fioritoni, Roberto Di Lorenzo, Chiara Colombi, Miriam Fogli, Marilina Amabile, Nicoletta Testoni, Antonio De Vivo, Michele Baccarani

Blood (2009) 114 (22): 860.

https://doi.org/10.1182/blood.V114.22.860.860

Published: 2009

Journal Articles

Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.

Blood (2009) 114 (22): 1868.

https://doi.org/10.1182/blood.V114.22.1868.1868

Published: 2009

Journal Articles

Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.

Patrizia Tosi, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Eugenio Salizzoni, MD, Giulia Perrone, MD, Michela Ceccolini, MD, Annamaria Brioli, MD, Maria C. Pallotti, MD, Lucia Pantani, MD, Antonio de Vivo, MD, Michele Baccarani, MD, Michele Cavo, MD

Blood (2007) 110 (11): 4728.

https://doi.org/10.1182/blood.V110.11.4728.4728

Published: 2007

Journal Articles

Rituximab Combined with M/VACOP-B and Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL): A Prospective Italian Phase II IIL Study.

Maurizio Martelli, MD, Vittorio Stefoni, MD, Giuseppina Cabras, MD, Sergio Cortellazzo, MD, Ercole Brusamolino, MD, Alessandro Levis, MD, Barbara Botto, MD, Antonio De Vivo, MD, Fiammetta Natalino, MD, Finolezzi Erica, MD, Robert Foa, MD, Pier Luigi Zinzani, MD

Blood (2006) 108 (11): 4697.

https://doi.org/10.1182/blood.V108.11.4697.4697

Published: 2006

Journal Articles

Fludarabine Based Regimen (FLAI) Is an Effective Treatment for Induction of Multidrug Resistant Pgp-Positive Acute Myeloid Leukemia Patients.

Blood (2005) 106 (11): 1857.

https://doi.org/10.1182/blood.V106.11.1857.1857

Published: 2005

Journal Articles

Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.

Blood (2005) 106 (11): 375.

https://doi.org/10.1182/blood.V106.11.375.375

Published: 2005

Journal Articles

Superior Complete Remission/Very Good Partial Remission Rate with Peri-Transplant Administration of Thalidomide-Dexamethasone for Newly Diagnosed Multiple Myeloma.

Michele Cavo, MD, Elena Zamagni, MD, Patrizia Tosi, MD, Delia Cangini, MD, Paola Tacchetti, MD, Claudia Cellini, MD, Nicoletta Testoni, PhD, Chiara Nicci, PhD, Antonio de Vivo, MD, Giulia Perrone, MD, Michela Ceccolini, MD, Michele Baccarani, MD

Blood (2005) 106 (11): 5474.

https://doi.org/10.1182/blood.V106.11.5474.5474

Published: 2005

Journal Articles

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

Michele Cavo, Elena Zamagni, Patrizia Tosi, Paola Tacchetti, Claudia Cellini, Delia Cangini, Antonio de Vivo, Nicoletta Testoni, Chiara Nicci, Carolina Terragna, Tiziana Grafone, Giulia Perrone, Michela Ceccolini, Sante Tura, Michele Baccarani, for the writing committee of the Bologna 2002 study

Blood (2005) 106 (1): 35–39.

https://doi.org/10.1182/blood-2005-02-0522

Published: 2005

Journal Articles

Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia

Blood (2004) 104 (13): 4245–4251.

https://doi.org/10.1182/blood-2004-03-0826

Published: 2004

Journal Articles

Efficacy and Toxicity of FLAI vs ICE for Induction Treatment of Newly Diagnosed AML Patients, Younger Than 60 Years.

Blood (2004) 104 (11): 878.

https://doi.org/10.1182/blood.V104.11.878.878

Published: 2004

Journal Articles

Imatinib in the Treatment of CML Patients ≥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.

Simona Bassi, MD, Fausto Castagnetti, MD, Marilina Amabile, BD, Barbara Giannini, BD, Daniela Cilloni, MD, Barbara Izzo, BD, Antonio De Vivo, MD, Simona Luatti, BD, Nicoletta Testoni, BD, Giovanna Rege-Cambrin, MD, Ilaria Iacobucci, BD, Enrico Gottardi, BD, Fabrizio Pane, MD, Francesco Salvatore, MD, Alessandra Dorigo, MD, Giuseppe Saglio, MD, Giovanni Martinelli, MD, Gianantonio Rosti, MD, Michele Baccarani, MD

Blood (2004) 104 (11): 2935.

https://doi.org/10.1182/blood.V104.11.2935.2935

Published: 2004

Journal Articles

Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML.

Blood (2004) 104 (11): 4672.

https://doi.org/10.1182/blood.V104.11.4672.4672

Published: 2004

Journal Articles

Superiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma.

Michele Cavo, Claudia Cellini, Elena Zamagni, Patrizia Tosi, Delia Cangini, Paola Tacchetti, Antonio De Vivo, Giulia Perrone, Roberto Massimo Lemoli, Sante Tura, Michele Baccarani

Blood (2004) 104 (11): 536.

https://doi.org/10.1182/blood.V104.11.536.536

Published: 2004

Journal Articles

Superiority of First-Line Thalidomide-Dexamethasone over Vincristine-Doxorubicin-Dexamethasone in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Michele Cavo, Paola Tacchetti, Elena Zamagni, Patrizia Tosi, Delia Cangini, Claudia Cellini, Nicoletta Testoni, Antonio De Vivo, Giulia Perrone, Sante Tura, Michele Baccarani

Blood (2004) 104 (11): 1489.

https://doi.org/10.1182/blood.V104.11.1489.1489

Published: 2004

NARROW

A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line

Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.

Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.

Rituximab Combined with M/VACOP-B and Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL): A Prospective Italian Phase II IIL Study.

Fludarabine Based Regimen (FLAI) Is an Effective Treatment for Induction of Multidrug Resistant Pgp-Positive Acute Myeloid Leukemia Patients.

Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.

Superior Complete Remission/Very Good Partial Remission Rate with Peri-Transplant Administration of Thalidomide-Dexamethasone for Newly Diagnosed Multiple Myeloma.

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia

Efficacy and Toxicity of FLAI vs ICE for Induction Treatment of Newly Diagnosed AML Patients, Younger Than 60 Years.

Imatinib in the Treatment of CML Patients ≥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.

Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML.

Superiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma.

Superiority of First-Line Thalidomide-Dexamethasone over Vincristine-Doxorubicin-Dexamethasone in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only